Loading...

Everest Medicines Limited

1952.HKHKSE
Healthcare
Biotechnology
HK$63.75
HK$6.55(11.45%)

Everest Medicines Limited 1952.HK Peers

See (1952.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1952.HKHK$63.75+11.45%20.2B-17.57-HK$3.54N/A
1801.HKHK$79.30+2.52%129.5B-1306.67-HK$0.06N/A
2269.HKHK$25.65+1.99%104.4B30.18HK$0.85N/A
1177.HKHK$5.33+0.57%94.1B47.82HK$0.11+1.33%
9926.HKHK$92.80+0.32%82.4B-141.46-HK$0.65N/A
1530.HKHK$24.25+6.83%55.8B25.43HK$0.93+1.06%
3759.HKHK$16.68+4.64%42.7B14.42HK$1.15N/A
9995.HKHK$55.25-0.54%37.2B-18.27-HK$2.98N/A
6821.HKHK$78.20+5.11%34.7B25.55HK$3.08+1.53%
1877.HKHK$21.50+2.87%33.9B-14.61-HK$1.42N/A
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1952.HK vs 1801.HK Comparison

1952.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1952.HK stands at 20.2B. In comparison, 1801.HK has a market cap of 129.5B. Regarding current trading prices, 1952.HK is priced at HK$63.75, while 1801.HK trades at HK$79.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1952.HK currently has a P/E ratio of -17.57, whereas 1801.HK's P/E ratio is -1306.67. In terms of profitability, 1952.HK's ROE is -0.24%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 1952.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1952.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;